Most Recent
Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.
A $37.75 million settlement has been reached in a shareholder class action against Estia Health that accused the aged care provider of failing to disclose difficulties in its 2015 and 2016 acquisition strategy.
US pharmaceutical giant Merck Sharp & Dohme has taken Sandoz to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Janumet and Januvia.
GetSwift has been criticised for its "quite unfair attack" on a Federal Court judge who refused to disqualify himself from hearing a shareholder class action against the logistics software company after presiding over ASIC's civil penalty proceeding against the company.
South Korean car maker Hyundai is facing a possible class action after it recalled over 90,000 cars earlier this month over safety concerns.
A judge has ordered a Melbourne-based law firm to stop acting for property company Xriso in a case against a former client over the terms of a deposit for a $51 million Werribee development in which the firm's managing partner is likely to be a key witness.
The directors of steel giant Arrium, which collapsed owing $4 billion in debts, should have known earlier that the company was in a "liquidity crisis" and was trading while insolvent, liquidators for the company allege.
Counsel for Queensland-based NQCranes has lashed out at the ACCC for seeking to amend its cartel action against the crane company, telling a court the regulator had been warned for months that the case was deficient.
A French geographical indication body has triumphed in its opposition to a bid to trade mark the name 'Chateau Roquehort' for dairy products, with a delegate finding that Australians would wrongly associate the name with blue cheeses from France.
US biotech company Gen-Probe's bid for the removal of rival Beckman Coulter's 'Access' trade marks will be heard alongside its appeal of a ruling from the Trade Marks Office denying the company's bid to expand its 'Open Access' trade mark to Australia.